Literature DB >> 18708360

Chemokine decoy receptor d6 plays a negative role in human breast cancer.

Feng-Ying Wu1, Zhou-Luo Ou, Lan-Yun Feng, Jian-Min Luo, Lei-Ping Wang, Zhen-Zhou Shen, Zhi-Min Shao.   

Abstract

Chemokine binding protein D6 is a promiscuous decoy receptor that can inhibit inflammation in vivo; however, the role it plays in cancer is not well known yet. In this study, we showed for the first time that human breast cancer differentially expressed D6 and the expression could be regulated by some cytokines. More importantly, overexpression of D6 in human breast cancer cells inhibits proliferation and invasion in vitro and tumorigenesis and lung metastasis in vivo. This inhibition is associated with decreased chemokines (e.g., CCL2 and CCL5), vessel density, and tumor-associated macrophage infiltration. Furthermore, D6 expression is inversely correlated to lymph node metastasis as well as clinical stages, but positively correlated to disease-free survival rate in cancer patients. Therefore, D6 plays a negative role in the growth and metastasis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18708360     DOI: 10.1158/1541-7786.MCR-07-2108

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  33 in total

Review 1.  Chemokines in health and disease.

Authors:  Dayanidhi Raman; Tammy Sobolik-Delmaire; Ann Richmond
Journal:  Exp Cell Res       Date:  2011-01-09       Impact factor: 3.905

2.  Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting.

Authors:  Stacey L Hembruff; Nikki Cheng
Journal:  Cancer Ther       Date:  2009-04-14

Review 3.  Chemokine Receptor Antagonists: Role in Oncology.

Authors:  Sean Kraus; Thomas Kolman; Austin Yeung; Dustin Deming
Journal:  Curr Oncol Rep       Date:  2021-09-04       Impact factor: 5.075

4.  Absence of multiple atypical chemokine binders (ACBs) and the presence of VEGF and MMP-9 predict axillary lymph node metastasis in early breast carcinomas.

Authors:  Xiao-Hua Zeng; Zhou-Luo Ou; Ke-Da Yu; Lan-Yun Feng; Wen-Jing Yin; Jing Li; Zhen-Zhou Shen; Zhi-Min Shao
Journal:  Med Oncol       Date:  2014-08-06       Impact factor: 3.064

5.  HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma.

Authors:  Anne Nguyen Kovochich; Michael Arensman; Anna R Lay; Nagesh P Rao; Timothy Donahue; Xinmin Li; Samuel W French; David W Dawson
Journal:  Cancer       Date:  2012-08-22       Impact factor: 6.860

Review 6.  Neutrophil diversity and plasticity in tumour progression and therapy.

Authors:  Sebastien Jaillon; Andrea Ponzetta; Diletta Di Mitri; Angela Santoni; Raffaella Bonecchi; Alberto Mantovani
Journal:  Nat Rev Cancer       Date:  2020-07-21       Impact factor: 60.716

7.  Moutan Cortex Radicis inhibits inflammatory changes of gene expression in lipopolysaccharide-stimulated gingival fibroblasts.

Authors:  Cheol-Sang Yun; Yeong-Gon Choi; Mi-Young Jeong; Je-Hyun Lee; Sabina Lim
Journal:  J Nat Med       Date:  2012-10-20       Impact factor: 2.343

Review 8.  Potential combinatorial effects of recombinant atypical chemokine receptors in breast cancer cell invasion: A research perspective.

Authors:  Ai Lan Chew; Wee Yee Tan; Boon Yin Khoo
Journal:  Biomed Rep       Date:  2013-01-21

Review 9.  Immune regulation by atypical chemokine receptors.

Authors:  Robert J B Nibbs; Gerard J Graham
Journal:  Nat Rev Immunol       Date:  2013-11       Impact factor: 53.106

Review 10.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.